Compare · GNFT vs IVA
GNFT vs IVA
Side-by-side comparison of GENFIT S.A. (GNFT) and Inventiva S.A. (IVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. GNFT focuses on Biotechnology: Biological Products (No Diagnostic Substances), while IVA focuses on Biotechnology: Pharmaceutical Preparations.
- IVA is the larger of the two at $734.8M, about 4.3x GNFT ($171.9M).
- IVA has hit the wire 4 times in the past 4 weeks while GNFT has been quiet.
- IVA has more recent analyst coverage (17 ratings vs 3 for GNFT).
- Company
- GENFIT S.A.
- Inventiva S.A.
- Price
- -
- -
- Market cap
- $171.9M
- $734.8M
- 1M return
- -
- -21.33%
- 1Y return
- -
- -39.05%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 0
- 4
- Recent ratings
- 3
- 17
GENFIT S.A.
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Latest GNFT
- SEC Form 15F-12B filed by GENFIT S.A.
- SEC Form S-8 POS filed by GENFIT S.A.
- SEC Form RW filed by GENFIT S.A.
- SEC Form 6-K filed by GENFIT S.A.
- SEC Form 6-K filed by GENFIT S.A.
- SEC Form 25 filed by GENFIT S.A.
- SEC Form 6-K filed by GENFIT S.A.
- SEC Form 6-K filed by GENFIT S.A.
- SEC Form 6-K filed by GENFIT S.A.
- SEC Form 6-K filed by GENFIT S.A.
Latest IVA
- SEC Form 6-K filed by Inventiva S.A.
- Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
- SEC Form 6-K filed by Inventiva S.A.
- Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
- Inventiva to Present Multiple Abstracts at Paris MASH 2026
- SEC Form 6-K filed by Inventiva S.A.
- Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
- SEC Form 6-K filed by Inventiva S.A.
- Inventiva Appoints Chris Benecchi as Chief Operating Officer
- Amendment: SEC Form 6-K/A filed by Inventiva S.A.